Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2026-02-10 00:00:00 ET · period of report 2026-02-09 · accession 0001193125-26-043814 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-10 | 2026-02-09 | SNDX | Metzger Michael A | CEO, Dir | S - Sale | $21.03 | -17.2K | 491.7K | -3% | -$360.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-09 | S | D | 17,159 | $21.03 | 491,690 | D | — | — |